Core Insights - Boston Scientific Corporation (BSX) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 80 cents, a 14.3% increase from the previous year, surpassing the Zacks Consensus Estimate by 2.6% and exceeding the company's guidance of 77-79 cents [1][2] - The company's full-year adjusted EPS reached $3.06, marking a 21.9% increase from 2024, also exceeding the Zacks Consensus Estimate by 0.7% and the 2025 guidance range of $3.02-$3.04 [2] Revenue Performance - Fourth-quarter revenues totaled $5.29 billion, reflecting a 15.9% year-over-year increase on a reported basis and 14.3% on an operational basis, with organic growth of 12.7% [3] - For the full year 2025, revenues were $20.07 billion, up 19.9% on a reported basis, 19.2% operationally, and 15.8% organically compared to 2024 [4] Regional Revenue Breakdown - In Q4, revenues increased by 17% in the United States, 12.4% in Europe, the Middle East and Africa (EMEA), 15.2% in the Asia Pacific, and 15.9% in Latin America and Canada [5] Segment Performance - MedSurg revenues in Q4 were $1.81 billion, up 15.9% year over year, with Endoscopy generating $760 million (8.2% organic growth) and Urology revenues at $717 million (3.2% organic growth) [7] - The Cardiovascular segment generated $3.48 billion in Q4 revenues, an 18.2% increase reported and 16.1% organically year over year [10] Margin Analysis - The gross margin expanded by 172 basis points to 69.6%, while adjusted operating margin increased by 180 basis points to 24% despite rising costs [11] Future Outlook - For 2026, Boston Scientific anticipates net sales growth of approximately 10.5-11.5% on a reported basis and 10-11% organically, with adjusted EPS expected in the range of $3.43-$3.49 [12] - Q1 2026 revenue growth is projected at 10.5-12% on a reported basis and 8.5-10% organically, with adjusted earnings expected between 78-80 cents per share [13] Strategic Developments - The company achieved broad regulatory approvals and clinical milestones across various franchises, including strategic acquisitions to enhance its vascular and neuromodulation portfolio [15]

Core Insights - Thermo Fisher Scientific Inc. (TMO) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57, exceeding the Zacks Consensus Estimate by 2.1% and reflecting a year-over-year increase of 7.7% [1][9] - The company's full-year adjusted EPS reached $22.87, surpassing the Zacks Consensus Estimate by 0.6% and showing a 4.6% year-over-year growth [2] Revenue Performance - TMO's revenues for the fourth quarter increased by 7.1% year over year to $12.22 billion, exceeding the Zacks Consensus Estimate by 2.3% [3][9] - For the full year, revenues rose 3.9% year over year to $44.56 billion, also surpassing the Zacks Consensus Estimate by 0.6% [3] Segment Analysis - Life Sciences Solutions segment revenues (24.1% of total revenues) grew by 13.5% year over year to $2.95 billion [4] - Analytical Instruments segment revenues (18.1%) increased by 1.4% year over year to $2.22 billion [5] - Specialty Diagnostics segment revenues (10%) rose by 5.2% year over year to $1.22 billion [6] - Laboratory Products and Biopharma Services segment revenues (52.2%) increased by 7.4% year over year to $6.38 billion [7] Margin and Cost Analysis - The gross margin for the fourth quarter was 41.5%, contracting by 150 basis points year over year due to a 10% rise in the cost of revenues [8] - Selling, general, and administrative expenses increased by 7.1% to $1.98 billion, while research and development expenses decreased by 4.5% year over year to $357 million [8] Financial Position - At the end of the fourth quarter, TMO had cash and cash equivalents and short-term investments totaling $10.11 billion, a significant increase from $3.55 billion at the end of the third quarter [10] - Cumulative net cash from operating activities at the end of the fourth quarter was $7.82 billion, down from $8.67 billion a year ago [10] Strategic Developments - TMO made several high-impact product launches in the fourth quarter, including the Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, and received FDA approval for the Ion Torrent Oncomine Dx Target Test and the EXENT System, which are expected to support future growth [12][13]

Core Insights - Abbott Laboratories reported fourth-quarter 2025 adjusted EPS of $1.50, aligning with estimates and showing an 11.9% increase from the previous year [1] - Full-year 2025 adjusted EPS was $5.15, reflecting a 10.3% year-over-year growth [1] - The company’s fourth-quarter revenues were $11.46 billion, a 4.4% increase year-over-year, but missed estimates by 2.8% [2] Financial Performance - The GAAP EPS for Q4 was $1.01, down from $5.27 in Q4 2024 [1] - Full-year 2025 worldwide sales reached $44.33 billion, up 5.7% year-over-year, but also missed estimates by 0.6% [2] - Gross profit for Q4 increased by 8.4% to $6.54 billion, with a gross margin expansion of 208 basis points to 57% [9] Segment Performance - Established Pharmaceuticals segment sales rose 9% to $1.38 billion, with organic sales growth of 7.1% [4] - Medical Devices segment sales increased 12.3% to $5.68 billion, driven by strong growth in Electrophysiology, Heart Failure, and Diabetes Care [5] - Nutrition sales declined 8.9% to $1.94 billion, with Pediatric Nutrition down 10.1% and Adult Nutrition down 8.2% [6][7] Future Guidance - For 2026, Abbott projects adjusted EPS between $5.55 and $5.80, with organic sales growth expected to be between 6.5% and 7.5% [11] - The first quarter of 2026 EPS is projected to be between $1.12 and $1.18 [11] Market Reaction - Following the earnings announcement, Abbott's stock fell 5.4% in pre-market trading [3] - The decline in Nutrition sales is attributed to lower sales volumes and strategic pricing actions [12]

Group 1 - Brandes Small Cap Value Fund reported a return of 11.16% for Class I Shares in Q3 2025, underperforming its benchmarks, the Russell 2000 Index at 12.39% and the Russell 2000 Value Index at 12.60% [1] - The fund highlighted Globant S.A. (NYSE:GLOB) as a key investment, which had a one-month return of 11.28% but experienced a significant decline of 68.83% over the past 52 weeks [2] - Globant S.A. generated revenues of $617.1 million in Q3 2025, reflecting a year-over-year increase of 0.4% and a sequential increase of 0.5% [4] Group 2 - The small-cap investment committee of Brandes Small Cap Value Fund purchased shares in Globant S.A. along with Prestige Consumer Healthcare and Sonoco Products Company [3] - At the end of Q3 2025, 32 hedge fund portfolios held Globant S.A., an increase from 26 in the previous quarter, indicating growing interest among institutional investors [4] - Despite the potential of Globant S.A. as an investment, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer better upside potential [4]

Financial Performance & Strategy - FY25 revenues reached $1,137.8 million[69] - The company achieved a 5-year revenue CAGR of 34%[17,69] - Adjusted EPS 5-year CAGR was +88%[17] - Organic revenue 5-year CAGR was +24%[17,69] - Adjusted FY25 Free Cash Flow reached $243291 thousand[49,75] - Net leverage was significantly reduced to 24x[49] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[51] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[45] FY26 Outlook - Expected revenue for FY26 is projected to be between $1,100 to $1,115 million[59] - Projected FY26 Non-GAAP Free Cash Flow is $245 million[59,77]

Financial Data and Key Metrics Changes - Q1 sales were approximately $250 million, which was below the forecast of $258 million to $260 million, representing a year-over-year decline largely due to supply chain issues and lower sales in eye care [5][10] - Gross margin expanded by 150 basis points to 56.2%, attributed to cost savings efforts [6][12] - Diluted EPS was $0.95, up approximately 6% from the adjusted prior year, despite the sales miss [7][14] - Free cash flow reached a record $78 million, enabling capital deployment for shareholder value enhancement [7][15] Business Line Data and Key Metrics Changes - North America segment revenues decreased by 8.4%, while International segment revenues increased by 7.1% year-over-year [11][12] - The eye care segment faced significant supply constraints, impacting sales, while other segments like Dramamine and Fleet showed healthy consumption trends [6][12] Market Data and Key Metrics Changes - The International segment experienced organic sales growth of 7%, driven by broad-based sales growth [12] - E-commerce channel saw double-digit year-over-year consumption growth, indicating a long-term trend towards higher online purchasing [12] Company Strategy and Development Direction - The company announced the acquisition of Pillar Five to secure and expand long-term supply for eye care products, which is expected to improve supply stability in the second half of the year [9][17] - The company anticipates revenues for fiscal 2026 to be between $1.1 billion and $1.115 billion, with organic revenue expected to decline approximately 1.5% to 3% [20] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the start of the year but remains confident in the long-term growth opportunities of their consumer healthcare portfolio [19] - The company expects significant improvement in Clear Eye shipments in the second half of the year, despite current supply chain challenges [20][29] Other Important Information - The company maintained a leverage ratio of approximately 2.4 times and repurchased over 400,000 shares in Q1 [7][15] - The anticipated cost of tariffs for the full year is approximately $5 million, which the company expects to offset through strategic actions [13] Q&A Session Summary Question: Change in retail order patterns and inventory destocking - Management noted increased order volatility from retailers in July, disconnected from consistent consumption levels, impacting Q2 significantly [23][24] Question: Confidence in supply normalizing for Clear Eyes - Management expressed confidence in supply normalizing in the back half of the year, with new suppliers and a high-speed line expected to contribute [26][29] Question: Impact of bringing eye care manufacturing in-house on margins - Management indicated no meaningful movement in gross margin as a result of bringing manufacturing in-house, expecting it to be largely neutral to the P&L [36][39] Question: Outlook for cough and cold season - Management maintained the initial guidance for a modest decline in the cough and cold category, too early to tell at this point [42] Question: Inventory levels within segments - Management reported no meaningful ramp-up of inventory, indicating that current order patterns are disconnected from consumption [44] Question: Performance of Summer's Eve brand - Management expressed confidence in the continued positive momentum of the Summer's Eve brand for the remainder of the year [46] Question: International segment growth sustainability - Management expects to sustain international growth, projecting a long-term algorithm of over 5% for the segment [68]